Crossref
PSMA Radioligand Therapy: Success and Limitations to Date
European Urology Focus · 2026-10 · 12 (5) · 825-826
DOI: 10.1016/j.euf.2026.07.010 ↗Kurz gefasst
Fachartikel in der Zeitschrift European Urology Focus, 2026-10. Verfasst von Oliver Sartor. Beteiligte Einrichtung: Transformational Prostate Cancer Research Center, LCMC Hospitals, New Orleans, Louisiana, United States. Electronic address: oliversartor@icloud.com. Die Arbeit nennt 10 Literaturangaben.
Abstract (Originalsprache)
Kein Abstract verfügbar.
Autor:innen und Institutionen
- Transformational Prostate Cancer Research Center, LCMC Hospitals, New Orleans, Louisiana, United States. Electronic address: oliversartor@icloud.com.
Zitieren
APA
Sartor, O. (2026). PSMA Radioligand Therapy: Success and Limitations to Date. European Urology Focus, 12(5), 825-826. https://doi.org/10.1016/j.euf.2026.07.010
Vancouver
Sartor O. PSMA Radioligand Therapy: Success and Limitations to Date. European Urology Focus. 2026;12(5):825-826. doi:10.1016/j.euf.2026.07.010
BibTeX
@article{Sartor2026,
author = {Sartor, Oliver},
title = {PSMA Radioligand Therapy: Success and Limitations to Date},
journal = {European Urology Focus},
year = {2026},
volume = {12},
number = {5},
pages = {825--826},
doi = {10.1016/j.euf.2026.07.010}
}
EUVIMED